The oncogenic driving potential of USP9X was confirmed in several tumor types: loss of function of the gene in chronic myelogenous leukemia [54], hepatocellular [55] or colorectal carcinoma [56], bladder cancer [57] and B-cell ALL [58] leads to increased sensitivity to chemotherapy and to apoptosis. This evidence concerns the gene USP9X and neoplasm.